ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Cancer
Adenocarcinoma
Stomach Cancer
Ovarian Cancer
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Boston, MA, USA:

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

and radiation therapy in people with microsatellite stable pancreatic cancer.The names of the study interventions involved in this ...

Active, not recruiting
Metastatic Pancreatic Cancer
Pancreatic Cancer
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 2 other locations

This research study is studying an investigational therapy as a possible treatment for pancreatic cancer.The drugs involved in this...

Active, not recruiting
Pancreatic Cancer
Drug: Niraparib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 2 other locations

receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastro...

Active, not recruiting
Pancreatic Cancer
Radiation: Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Viewray

Boston, Massachusetts, United States and 12 other locations

3 study is to evaluate the efficacy of Kinisoquin as compared to the placebo in prevention of thromboembolic events in patients with metastatic pancreatic...

Enrolling
Metastatic Pancreatic Cancer
Venous Thromboembolism
Drug: Kinisoquin
Drug: Placebo

Phase 3

Quercis Pharma

Boston, Massachusetts, United States and 2 other locations

Locations recently updated

This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer...

Active, not recruiting
Microsatellite Stable Colorectal Cancer
MSI High Colorectal Cancer
Drug: Nivolumab
Radiation: Radiation Therapy

Phase 2

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States

This research study is studying a combination of interventions as a possible treatment for pancreatic tumor.The interventions invol...

Active, not recruiting
Pancreatic Cancer
Drug: FOLFIRINOX
Radiation: SBRT

Phase 2

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 9 other locations

Locations recently updated

(focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer...

Begins enrollment in 2 months
Locally Advanced Pancreatic Cancer
Borderline Resectable Pancreatic Cancer
Device: IMD10
Drug: chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
IMGT Co., Ltd.

Boston, Massachusetts, United States and 4 other locations

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer...

Enrolling
Pancreatic Ductal Adenocarcinoma
Advanced Pancreatic Adenocarcinoma
Drug: Gemzar
Drug: Zentalis

Phase 2

Brandon Huffman, MD

Boston, Massachusetts, United States

is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic...

Enrolling
Locally Advanced Pancreatic Adenocarcinoma
Drug: Modified FOLFIRINOX
Combination Product: Acoustic Cluster Therapy

Phase 2

EXACT Therapeutics

Providence, Rhode Island, United States and 3 other locations

gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least on...

Active, not recruiting
Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Drug: Nab-paclitaxel
Drug: Botensilimab

Phase 2

Bruno Bockorny

Boston, Massachusetts, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems